Australia's largest stock trading and investment forum Australia's #1 stock forum

BOD

Click for more information

0.00%

2.4¢ bod science limited

Ann: Phase IIB Clinical Trial of Schedule 3, page-12

First 12 Last

Share
Profile

Follow
Keith2

759 Posts.

39

18/07/23

11:07

Post #: 68839756
Share

Originally posted by BH31: ↑

I am also very optimistic, but find the constant delays are very frustrating. If they say results will be available early July, they should not still be pending on 18 July. The same as providing an update on the OTC after 30 June, when it was due by 30 June for the Arrotex Agreement. It is very concerning if they didn't know before 3 July that the deadline had been extended. The same thing announcing the extension of the PK studies deadline on the day they were due.

Under promise, over deliver is an old one but one BOD should think about. Stop promoting "near term" events and including dates if they are repeatedly not met. Instead of early July, why not just say July or "the coming months". It is very misleading and reflects poorly on management.

The only good news is unless they extend the deadlines again, there should be lots of news flow in the coming weeks, and hopefully positive.

Expand

agreed, although pushbacks is not too uncommon in most sectors.. im not too fussed as i believe this is a pretty defining period for bod and its future.. hopefully they are using this time wisely and getting everything right..

BOD Price at posting: 9.0¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BUX

Buxton projects new graphite province discovery at WA Narryer play

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 6 more messages in this thread...

First 12 Last

Add BOD (ASX) to my watchlist